12/18
01:32 pm
capr
Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory [Yahoo! Finance]
Low
Report
Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory [Yahoo! Finance]
12/16
04:05 pm
capr
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
Low
Report
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
12/15
10:04 am
capr
Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at UBS Group AG.
Low
Report
Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at UBS Group AG.
12/15
09:03 am
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at B. Riley.
Low
Report
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at B. Riley.
12/10
03:37 pm
capr
Capricor: A Detailed Examination Of Hope-3 [Seeking Alpha]
Low
Report
Capricor: A Detailed Examination Of Hope-3 [Seeking Alpha]
12/10
07:21 am
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/8
08:13 am
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
Capricor Therapeutics (NASDAQ:CAPR) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
12/6
05:27 am
capr
How Recent Developments Are Rewriting the Story for Capricor Therapeutics [Yahoo! Finance]
Medium
Report
How Recent Developments Are Rewriting the Story for Capricor Therapeutics [Yahoo! Finance]
12/6
01:21 am
capr
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript [Seeking Alpha]
Medium
Report
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript [Seeking Alpha]
12/5
07:55 am
capr
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock [Yahoo! Finance]
Low
Report
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock [Yahoo! Finance]
12/5
06:35 am
capr
Capricor Therapeutics prices $150M stock offering [Seeking Alpha]
Low
Report
Capricor Therapeutics prices $150M stock offering [Seeking Alpha]
12/5
06:15 am
capr
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
Medium
Report
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
12/4
04:57 pm
capr
Capricor Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
Capricor Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
12/4
04:01 pm
capr
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
High
Report
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
12/4
12:01 pm
capr
Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at Maxim Group.
Medium
Report
Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at Maxim Group.
11/24
09:00 am
capr
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
High
Report
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
11/11
06:02 pm
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at Roth Capital.
Medium
Report
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at Roth Capital.
11/11
12:30 am
capr
Capricor Therapeutics Inc (CAPR) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
Medium
Report
Capricor Therapeutics Inc (CAPR) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
11/10
11:24 pm
capr
Capricor signals pivotal HOPE-3 data imminent as FDA review process advances for deramiocel [Seeking Alpha]
Medium
Report
Capricor signals pivotal HOPE-3 data imminent as FDA review process advances for deramiocel [Seeking Alpha]
11/10
04:04 pm
capr
Capricor Therapeutics, Inc. GAAP EPS of -$0.54 beats by $0.01 [Seeking Alpha]
Medium
Report
Capricor Therapeutics, Inc. GAAP EPS of -$0.54 beats by $0.01 [Seeking Alpha]
11/10
04:01 pm
capr
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
High
Report
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/10
10:16 am
capr
Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm
Medium
Report
Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm
11/4
04:05 pm
capr
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
Low
Report
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
11/3
09:15 am
capr
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel
Medium
Report
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel
10/31
09:15 am
capr
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
Low
Report
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10